Repositive has announced today that Yashraj Biotechnology will be joining its global network of CRO partners. With this new partnership, Repositive is continuing to grow its global reach and cancer model search capabilities to support more biopharma customers in sourcing the right preclinical cancer models for their research.
“We are excited to see how quickly our preclinical cancer model network is expanding to support Repositive’s recent pivot towards our Cancer Model Scout search service. These new partnerships are helping to uniquely position us to perform even the most complex of model searches for our biopharma customers, especially those looking for very specific or hard-to-find models.” – said Catherine McDermott, CEO of Repositive
Repositive’s core offering is a subscription package with a specialist and cost-effective cancer model search service, the Cancer Model Scout (CMS), which connects cancer researchers to the right preclinical models and CROs, based on individual study requirements. In just 2-4 weeks, Repositive’s team of expert bioinformaticians can conduct a detailed cancer model search across their extended CRO network and compile a comprehensive list of models matches, complete with a bioinformatics report of methods. Cancer Model Scout searches are part of a tailored subscription package and include access to Repositive’s beta-Cancer Model Platform, an online directory of over 8000 preclinical cancer models. Learn more about Repositive’s cancer models, data and services here.
Yashraj Biotechnology (YBL) is a multinational CRO, headquartered in Mumbai, India, with presence in Berlin, Seoul, San Diego and a continuous expansion of the global footprint. YBL has developed third party-validated preclinical cancer models for end-to-end solutions for drug discovery and development including target identification and lead validation, drug efficacy testing, safety profiling, target expansion as well as disease modelling.
YBL offers unique cancer models that recapitulate clinical response of known drugs and thus show promise for testing INDs. Models include cancer organoids using primary cancer cells from patients with cancers originating in different tissues, cancer cell-line models etc. (for Breast Cancer, Ovarian Cancer and several other Organs). These cancer platforms are available in 2D as well as 3D formats for drug testing and disease modelling.
YBL also has isogenic models derived from Induced pluripotent stem cells (iPSCs), Mesenchymal Stem Cells (MSCs) and differentiated derivatives (e.g. Functionally mature Cardiac, Hepatic and Neural Organoids) from Cancer Patients as well as Healthy Volunteers to complement the in vitro drug testing for the cancer models. YBL has a bio-bank to support your drug discovery needs in the Oncology space, with a wide-range of isogenic bio-specimens (FFPE and Snap Frozen Cancer biopsies, Adjacent Normal Biopsies, Primary Cancer Cells, Primary Somatic Cells – PBMCs, Adipose derived MSCs, iPSCs and Derivatives, Serum/ Plasma/ Urine for Biomarker Studies) available from patients with cancers originating in different tissues.
YBL also offers customised services for drug screening and toxicology, including bio-banking, customised cell model development and oncology drug screening services on Cancer Organoids and iPSC-derived Mini Organs (Liver, Heart, Brain) as well as downstream molecular and functional assay services. Additionally, YBL offers Xenograft development (CDX/PDX) and drug profiling services including Pharmacokinetics and Pharmacodynamics. The in vitro gene editing platform using CRISPR technology has also been established for developing customized disease models for drug discovery.
These human models are recommended for studying the safety and efficacy of drugs, and predicting their therapeutic index before entering into clinical studies that will build-up the success rate of a drug. These models have been validated with different approved drugs and safety and efficacy profiles were similar to the clinical outcomes. These models can also be explored for the expansion of therapeutic indications during clinical studies.